ISAR-TRIPLE Antiplatelet Duration Algorithm

Clinical calculation support · Verify results before clinical use

Clinical decision support

Review the post-PCI antithrombotic context. This tool summarizes evidence and guideline considerations; it does not calculate a validated treatment score.

Trial +
guideline
Evidence

Patient and anticoagulation context

These fields organize the clinical context. They are not combined into an unvalidated numerical score.

PCI and ischemic context

The treating interventional cardiologist should define procedural complexity and stent-thrombosis risk; these fields do not independently validate a longer triple-therapy course.

Bleeding and thromboembolic context

HAS-BLED identifies modifiable bleeding risks and need for review; it should not be used alone to withhold indicated anticoagulation. CHA₂DS₂-VASc informs thromboembolic risk in AF and is not a validated proxy for coronary ischemic risk or triple-therapy duration.

Evidence-based interpretation

Complete the clinical context

Select the relevant fields and choose “Review strategy” to display the evidence summary and key considerations.

Key distinction

ISAR-TRIPLE compared 6 weeks with 6 months of clopidogrel within triple therapy after DES implantation. It did not establish a universal duration rule or a patient-level risk score.

Do not change or stop antiplatelet or anticoagulant treatment solely on the basis of this educational tool.

Clinical context and evidence

ISAR-TRIPLE was an open-label randomized trial of 614 patients receiving oral anticoagulation who underwent drug-eluting stent implantation. Participants received aspirin plus oral anticoagulation and were randomized to clopidogrel for 6 weeks or 6 months.

Trial outcome at 9 months6 weeks6 monthsInterpretation
Composite primary endpoint9.8%8.8%HR 1.14; 95% CI 0.68–1.91; p=0.63. No significant difference.
Ischemic endpoint4.0%4.3%No significant difference.
TIMI major bleeding5.3%4.0%No significant difference in the overall comparison.

How to interpret the trial

  • The trial did not show superiority of 6 weeks over 6 months for its composite net clinical outcome.
  • It compared specific clopidogrel durations in patients on aspirin and oral anticoagulation after DES implantation; it did not test every contemporary regimen or stent type.
  • The study was conducted before many current DOAC-based and early aspirin-discontinuation strategies became standard. Its regimen should not be treated as a current universal default.

Contemporary guideline context

The 2025 ACC/AHA acute coronary syndromes guideline recommends that, in patients with ACS who require oral anticoagulation, aspirin generally be discontinued 1–4 weeks after PCI while continuing an oral anticoagulant and a P2Y₁₂ inhibitor (preferably clopidogrel). Individual procedural and ischemic considerations may affect the decision, including selected patients at high stent-thrombosis risk. Confirm the current applicable guideline and the patient's full clinical context before treatment decisions.

Practical review checklist

  • Confirm the indication for anticoagulation and the correct anticoagulant/dose; mechanical valves generally require a vitamin K antagonist rather than a DOAC.
  • Confirm PCI details, stent characteristics, procedural complexity, ACS presentation, and any history of stent thrombosis.
  • Assess bleeding history, renal function, concomitant drugs, anemia, blood pressure, and modifiable bleeding risks.
  • Document the intended aspirin stop date, P2Y₁₂ inhibitor plan, anticoagulation plan, and follow-up/reassessment arrangements.
  • Consider gastroprotection when indicated and avoid unnecessary concomitant medicines that increase bleeding risk.

What this tool does not do

It does not estimate an individual probability of bleeding or ischemia, calculate a validated ISAR-TRIPLE score, prescribe a specific drug dose, or replace a clinician's assessment. HAS-BLED and CHA₂DS₂-VASc are displayed as context only and are not combined into a new score.

Selected references

Fiedler KA, Maeng M, Mehilli J, et al. ISAR-TRIPLE Trial.Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. J Am Coll Cardiol. 2015;65(16):1619–1629. DOI: 10.1016/j.jacc.2015.02.050. PMID: 25908066.
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.J Am Coll Cardiol. 2025. Official publication: doi:10.1016/j.jacc.2024.11.009.
American Heart Association. Top Things to Know: 2025 Guideline for Acute Coronary Syndromes.Official guideline summary: AHA professional guidance.
Clinical disclaimer: This educational decision-support tool is not a substitute for clinical judgment or local protocols. Antithrombotic choices depend on the indication for oral anticoagulation, PCI and stent details, bleeding and ischemic risks, renal function, drug interactions, and current guidance. Do not start, stop, or alter prescribed antiplatelet or anticoagulant treatment without the treating clinician's direction.